Product Code: ETC7642361 | Publication Date: Sep 2024 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Ireland Transthyretin Amyloidosis Treatment Market is witnessing growth due to increasing awareness, improved healthcare infrastructure, and rising prevalence of amyloidosis. The market is primarily driven by the availability of novel therapies and ongoing research and development activities focused on developing more effective treatment options. Key players in the market are investing in innovative drug development to address the unmet medical needs of amyloidosis patients. Additionally, collaborations between pharmaceutical companies and research institutions are further propelling market growth. The market is expected to continue expanding as more advanced treatment options become available, catering to the growing patient population in Ireland.
Currently, the Ireland Transthyretin Amyloidosis Treatment Market is witnessing a growing focus on the development of novel therapies and increasing awareness among healthcare professionals and patients. With the approval of new treatments such as RNA interference (RNAi) drugs and gene-silencing therapies, there is a shift towards more targeted and effective approaches for managing this rare disease. Additionally, collaborations between pharmaceutical companies and research institutions are creating opportunities for the advancement of treatment options in the market. The rising prevalence of transthyretin amyloidosis and improved diagnosis rates are also driving the demand for innovative therapies, presenting a favorable landscape for market growth in Ireland. Overall, the market is poised for further expansion with the introduction of advanced treatment modalities and increased investment in research and development.
In the Ireland Transthyretin Amyloidosis Treatment Market, several challenges are faced, including limited awareness among healthcare professionals leading to underdiagnosis, high treatment costs impacting patient access, and a lack of specific therapies approved for the condition. The rarity of transthyretin amyloidosis also poses a challenge in conducting clinical trials and developing new treatment options. Additionally, the complexity of the disease and its varying clinical manifestations make it challenging to diagnose and manage effectively. Furthermore, the need for specialized centers with expertise in treating amyloidosis adds another layer of difficulty in ensuring optimal care for patients. Overcoming these challenges will require increased education and awareness efforts, as well as continued research and development of innovative therapies tailored to the specific needs of patients with transthyretin amyloidosis in Ireland.
The Ireland Transthyretin Amyloidosis Treatment Market is primarily driven by factors such as the increasing prevalence of transthyretin amyloidosis in the country, growing awareness among healthcare professionals and patients, advancements in diagnostic techniques, and the launch of novel treatment options. Additionally, the rising geriatric population, who are more susceptible to developing this condition, and the government initiatives to improve access to healthcare services further contribute to the market growth. Moreover, collaborations between pharmaceutical companies and research institutions to develop innovative therapies for transthyretin amyloidosis are also fueling market expansion. Overall, the market is expected to witness significant growth due to these drivers in the coming years.
The Irish government has implemented various policies to support the treatment market for Transthyretin Amyloidosis (ATTR). These policies include the approval and reimbursement of specific ATTR treatments through the Health Service Executive (HSE), such as tafamidis and inotersen. The HSE also provides guidance on the appropriate use of these treatments, ensuring that patients have access to effective therapies. Additionally, the government focuses on promoting research and development in the field of ATTR treatment through funding initiatives and collaborations with pharmaceutical companies and research institutions. Overall, the government`s policies aim to improve access to innovative treatments, enhance patient outcomes, and drive advancements in the management of Transthyretin Amyloidosis in Ireland.
The Ireland Transthyretin Amyloidosis Treatment Market is expected to experience steady growth in the coming years, driven by factors such as an increasing prevalence of the disease, advancements in treatment options, and rising awareness among healthcare professionals and patients. The market is likely to see a rise in the adoption of novel therapies, including gene-silencing treatments and targeted therapies, which offer improved outcomes and disease management. Additionally, collaborations between pharmaceutical companies, research institutions, and healthcare providers are anticipated to drive innovation and expand the treatment landscape for Transthyretin Amyloidosis in Ireland. Overall, the market is poised for growth as efforts continue to enhance diagnosis, treatment, and patient care for this rare but serious condition.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Transthyretin Amyloidosis Treatment Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Transthyretin Amyloidosis Treatment Market - Industry Life Cycle |
3.4 Ireland Transthyretin Amyloidosis Treatment Market - Porter's Five Forces |
3.5 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Therapy, 2021 & 2031F |
3.7 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.8 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Ireland Transthyretin Amyloidosis Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Ireland Transthyretin Amyloidosis Treatment Market Trends |
6 Ireland Transthyretin Amyloidosis Treatment Market, By Types |
6.1 Ireland Transthyretin Amyloidosis Treatment Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By ATTR-PN, 2021- 2031F |
6.1.4 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By ATTR-CM, 2021- 2031F |
6.2 Ireland Transthyretin Amyloidosis Treatment Market, By Therapy |
6.2.1 Overview and Analysis |
6.2.2 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Targeted Therapy, 2021- 2031F |
6.2.3 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By OnpattroInotersen, 2021- 2031F |
6.2.4 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Vyndaqel/Vyndamax, 2021- 2031F |
6.2.5 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Supportive Therapy, 2021- 2031F |
6.2.6 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Pipeline Therapy, 2021- 2031F |
6.3 Ireland Transthyretin Amyloidosis Treatment Market, By Disease Type |
6.3.1 Overview and Analysis |
6.3.2 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Hereditary Transthyretin Amyloidosis, 2021- 2031F |
6.3.3 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Polyneuropathy, 2021- 2031F |
6.3.4 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Cardiomyopathy, 2021- 2031F |
6.3.5 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Mixed Type, 2021- 2031F |
6.3.6 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Wild Type Amyloidosis, 2021- 2031F |
6.4 Ireland Transthyretin Amyloidosis Treatment Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.4.3 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Specialty Pharmacies, 2021- 2031F |
6.4.4 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4.5 Ireland Transthyretin Amyloidosis Treatment Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
7 Ireland Transthyretin Amyloidosis Treatment Market Import-Export Trade Statistics |
7.1 Ireland Transthyretin Amyloidosis Treatment Market Export to Major Countries |
7.2 Ireland Transthyretin Amyloidosis Treatment Market Imports from Major Countries |
8 Ireland Transthyretin Amyloidosis Treatment Market Key Performance Indicators |
9 Ireland Transthyretin Amyloidosis Treatment Market - Opportunity Assessment |
9.1 Ireland Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Ireland Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Therapy, 2021 & 2031F |
9.3 Ireland Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.4 Ireland Transthyretin Amyloidosis Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Ireland Transthyretin Amyloidosis Treatment Market - Competitive Landscape |
10.1 Ireland Transthyretin Amyloidosis Treatment Market Revenue Share, By Companies, 2024 |
10.2 Ireland Transthyretin Amyloidosis Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |